Partnering Key To Bayer’s Eylea Good Start In Japan
This article was originally published in The Pink Sheet Daily
Executive Summary
Bayer's three new products – Eylea, Xarelto and Stivarga – are off to a good start in the marketplace, says interim pharma head Wolfgang Plischke. Eylea has 48% Japanese market share for wet AMD.